Evaluation of heteroscorpionate ligands as scaffolds for the generation of Ruthenium(II) metallodrugs in breast cancer therapy

The modular synthesis of the heteroscorpionate core is explored as a tool for the rapid development of ruthenium-based therapeutic agents. Starting with a series of structurally diverse alcohol-NN ligands, a family of heteroscorpionate-based ruthenium derivatives was synthesized, characterized, and evaluated as an alternative to platinum therapy for breast cancer therapy. In vitro, the antitumoral activity of the novel derivatives was assessed in a series of breast cancer cell lines using UNICAM-1 and cisplatin as metallodrug control. Through this approach, a bimetallic heteroscorpionate-based metallodrug (RUSCO-2) was identified as the lead compound of the series with an IC50 value range as low as 3-5 μM. Notably, RUSCO-2 was found to be highly cytotoxic in TNBC cell lines, suggesting a mode of action independent of the receptor status of the cells. As a proof of concept and taking advantage of the luminescent properties of one of the complexes obtained, uptake was monitored in human breast cancer MCF7 cell lines by fluorescence lifetime imaging microscopy (FLIM) to reveal that the compound is evenly distributed in the cytoplasm and that the incorporation of the heteroscorpionate ligand protects it from aqueous processes, conversion in another entity, or the loss of the chloride group. Finally, ROS studies were conducted, lipophilicity was estimated, the chloride/water exchange was studied, and stability studies in simulated biological media were carried out to propose structure-activity relationships.

Development of Metal Complexes for Treatment of Coronaviruses

Coronavirus disease (SARS-CoV-2) is a global epidemic. This pandemic, which has been linked to high rates of death, has forced some countries throughout the world to implement complete lockdowns in order to contain the spread of infection. Because of the advent of new coronavirus variants, it is critical to find effective treatments and vaccines to prevent the virus's rapid spread over the world. In this regard, metal complexes have attained immense interest as antibody modifiers and antiviral therapies, and they have a lot of promise towards SARS-CoV-2 and their suggested mechanisms of action are discussed, i.e., a new series of metal complexes' medicinal vital role in treatment of specific proteins or SARS-CoV-2 are described. The structures of the obtained metal complexes were fully elucidated by different analytical and spectroscopic techniques also. Molecular docking and pharmacophore studies presented that most of complexes studied influenced good binding affinity to the main protease SARS-CoV-2, which also was attained as from the RCSB pdb (Protein Data Bank) data PDB ID: 6 W41, to expect the action of metal complexes in contradiction of COVID-19. Experimental research is required to determine the pharmacokinetics of most of the complexes analyzed for the treatment of SARS-CoV-2-related disease. Finally, the toxicity of a metal-containing inorganic complex will thus be discussed by its capability to transfer metals which may bind with targeted site.

Synthesis, Characterization and Assessment of the Antioxidant Activity of Cu(II), Zn(II) and Cd(II) Complexes Derived from Scorpionate Ligands

Seeking to enrich the yet less explored field of scorpionate complexes bearing antioxidant properties, we, here, report on the synthesis, characterization and assessment of the antioxidant activity of new complexes derived from three scorpionate ligands. The interaction between the scorpionate ligands thallium(I) hydrotris(5-methyl-indazolyl)borate (TlTp^4Bo,5Me), thallium(I) hydrotris(4,5-dihydro-2H-benzo[g]indazolyl)borate (TlTp^a) and potassium hydrotris(3-tert-butyl- pyrazolyl)borate (KTp^tBu), and metal(II) chlorides, in dichloromethane at room temperature, produced a new family of complexes having the stoichiometric formula [M(Tp^4Bo,5Me)₂] (M = Cu, 1; Zn, 4; Cd, 7), [M(Tp^a)₂] (M = Cu, 2; Zn, 5; Cd, 8), [Cu(Hpz^tBu)₃Cl₂] (3), [Zn(Tp^tBu)Cl] (6) and [Cd(Bp^tBu)(Hpz^tBu)Cl] (9). The obtained metal complexes were characterized by Fourier transform infrared spectroscopy, proton nuclear magnetic resonance and elemental analysis, highlighting the total and partial hydrolysis of the scorpionate ligand Tp^tBu during the synthesis of the Cu(II) complex 3 and the Cd(II) complex 9, respectively. An assessment of the antioxidant activity of the obtained metal complexes was performed through both enzymatic and non-enzymatic assays against 1,1-diphenyl-2-picryl- hydrazyl (DPPH^·), 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS^+·), hydroxyl (HO^·), nitric oxide (NO^·), superoxide (O₂⁻) and peroxide (OOH^·) radicals. In particular, the complex [Cu(Tp^a)₂]⋅0.5H₂O (2) exhibited significant antioxidant activity, as good and specific activity against superoxide (O₂^−·), (IC50 values equal to 5.6 ± 0.2 μM) and might be identified as auspicious SOD-mimics (SOD = superoxide dismutase).

Novel Chemotherapeutic Agents - The Contribution of Scorpionates

The development of safe and effective chemotherapeutic agents is one of the uppermost priorities and challenges of medicinal chemistry and new transition metal complexes are being continuously designed and tested as anticancer agents. Scorpionate ligands have played a great role in coordination chemistry, since their discovery by Trofimenko in the late 1960s, with significant contributions in the fields of catalysis and bioinorganic chemistry. Scorpionate metal complexes have also shown interesting anticancer properties, and herein, the most recent (last decade) and relevant scorpionate complexes reported for application in medicinal chemistry as chemotherapeutic agents are reviewed. The current progress on the anticancer properties of transition metal complexes bearing homo- or hetero- scorpionate ligands, derived from bis- or tris-(pyrazol-1-yl)-borate or -methane moieties is highlighted.

The heteroscorpionate ligand 2,2-bis(3,5-dimethylpyrazol-1-yl)-1,1-diphenylethanol and an easy preparation of its tungsten complex

The heteroscorpionate ligand 2,2-bis(3,5-dimethylpyrazol-1-yl)-1,1-diphenylethanol, C24H26N4O, features in the solid state an intramolecular O—H...N hydrogen bond. A heteroscorpionate tungsten complex, cis-[2,2-bis(3,5-dimethylpyrazolyl)-1,1-diphenylethanolato]chloridodioxidotungsten(VI) tetrahydrofuran monosolvate, [W(C24H25N4O)ClO2]·C4H8O, was prepared by the simple mixing of solutions of the ligand and WOCl4 in tetrahydrofuran. The tungsten complex was isolated after standing for several weeks. The complex exhibits a κ3 N,N′,O-coordination of the ligand. This simple synthetic procedure allows access to the cis isomer in high yield without additional purification steps. The Hirshfeld surface analysis shows a change of the intermolecular contacts due to the coordination of the WO2Cl unit with the ligand molecule.

Magnesium, calcium and zinc [N2N'] heteroscorpionate complexes

A new family of sterically demanding N2N' heteroscorpionate pro-ligands (HC(tBu2pz)2SiMe2N(H)R (R = iPr, tBu, Ph, Xyl)) has been prepared via a straightforward modular synthetic route. An extensive study into the synthesis and characterisation of lithium, magnesium, calcium and zinc complexes supported by both 3,5-tBu and 3,5-Me substituted N2N' ligand families has been conducted. Attempted deprotonation of the pro-ligands with nBuLi afforded the corresponding lithium salts Li{HC(tBu2pz)2SiMe2NR} (R = iPr (1), tBu (2), Ph (3) and Xyl (4)) but air- and thermal-sensitivity limited the yields of these potentially useful precursors; only the sterically encumbered ligand system allowed clean reactivity. Magnesium methyl complexes Mg{HC(tBu2pz)2SiMe2NR}Me (R = iPr (5) and R = Ph (6)) were prepared using an excess of the Grignard reagent MeMgCl. Magnesium butyl complexes were synthesised in good yields using the dialkyl precursor MgnBu2 to afford Mg{HC(R'2pz)2SiMe2NR}nBu (R' = Me; R = iPr (7), tBu (8), Ad (9), Ph (10). R' = tBu; R = iPr (11), Ph (12)). Protonolylsis reactions were used to synthesise magnesium and calcium amide complexes Mg{HC(R'2pz)2SiMe2NR}{N(SiHMe2)2} (R' = Me; R = iPr (13), tBu (14), Ph (15). R' = tBu; R = Ph (16)) or Mg{HC(R'2pz)2SiMe2NR}{N(SiMe3)2} (R' = Me; R = iPr (17), tBu (18), Ph (19). R' = tBu; R = Ph (20)), and Ca{HC(R'2pz)2SiMe2NR}{N(SiMe2)2} (L) (R' = Me; L = thf; R = iPr (21), tBu (22), Ph (23). R' = tBu; L = none; R = Ph (24). Zinc methyl complexes Zn{HC(R'2pz)2SiMe2NR}Me (R' = Me; R = iPr (25), tBu (26), Ph (27). R' = tBu; R = Ph (28)) were prepared by reaction of the N2N' heteroscorpionate pro-ligands with ZnMe2. In preliminary studies, magnesium amide complexes 16 and 20 were evaluated as initiators for the ring-opening polymerisation (ROP) of ε-caprolactone (ε-CL) and rac-lactide (rac-LA). Although the overall polymerisation control was poor, 16 and 20 were found to be active initiators.

Synthesis of helical aluminium catalysts for cyclic carbonate formation

Helical aluminium complexes have been prepared and used as catalysts for cyclic carbonate synthesis.